Merck and Pfizer have entered into a worldwide (except Japan) collaboration for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes. Phase III ertugliflozin trials are expected to begin later this year.   Merck, through a subsidiary, and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-d...